Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Actinomycin D |
EINECS | 200-063-6 |
CAS No. | 50-76-0 | Density | 1.42 g/cm3 |
PSA | 359.98000 | LogP | 2.37360 |
Solubility | soluble in water | Melting Point |
251-253 °C |
Formula | C62H86N12O16 | Boiling Point | 1386 °C at 760 mmHg |
Molecular Weight | 1255.44 | Flash Point | 792.1 °C |
Transport Information | UN 3462 6.1/PG 2 | Appearance | red crystalline powder |
Safety | 53-36/37/39-45-1-28-22 | Risk Codes | 61-40-45-26/27/28 |
Molecular Structure | Hazard Symbols | T+ | |
Synonyms |
3H-Phenoxazine-1,9-dicarboxamide,2-amino-N,N'-bis(hexadecahydro-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-(7CI);Actinomycin C1 (6CI);1H-Pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecine, cyclic peptidederiv.;Actactinomycin A IV;Actinomycin 7;Actinomycin AIV;Actinomycin I1;Actinomycin IV;Actinomycin X1;Actinomycindioic D acid, dilactone;Chounghwamycin B;Cosmegen;Dactinomycin;Dilactone actinomycin D acid;Lyovac cosmegen;NCI C04682;Oncostatin K;Stereoisomer ofN,N'-[(2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)bis[carbonylimino[2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl]imino[2-(1-methylethyl)-1-oxo-2,1-ethanediyl]-1,2-pyrrolidinediylcarbonyl(methylimino)(1-oxo-2,1-ethanediyl)]]bis[N-methyl-L-valine]di-x-lactone; |
Article Data | 12 |
The Actinomycin D with the cas number 50-76-0. It is also called 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide name by IUPAC. It seems like bright red rhomboid prisms or red powder. It belongs to the flollowing product categories: (1)Antibiotics; (2)Antibiotic Explorer; (3)Intermediates & Fine Chemicals; (4)Peptides; (5)Pharmaceuticals; (6)Caspases/Apoptosis. Actinomycin D is stable, but light sensitive, especially in dilute solution. And it is incompatible with strong acids, strong bases, strong oxidizing agents. Besides, it is quite combustible. It is should be stored at 2-8°C.
Properties of Actinomycin D are: (1)ACD/LogP: -0.33 ; (2)# of Rule of 5 Violations: 0 ; (3)ACD/LogD (pH 5.5): -2.83 ; (4)ACD/LogD (pH 7.4): -2.83 ; (5)ACD/BCF (pH 5.5): 1 ; (6)ACD/BCF (pH 7.4): 1 ; (7)ACD/KOC (pH 5.5): 1 ; (8)ACD/KOC (pH 7.4): 1 ; (9)#H bond acceptors: 3 ; (10)#H bond donors: 3 ; (11)#Freely Rotating Bonds: 2 ; (12)Polar Surface Area: 29.54Å2 ; (13)Index of Refraction: 1.464 ; (14)Molar Refractivity: 25.64 cm3 ; (15)Molar Volume: 92.9 cm3 ; (16)Polarizability: 10.16 ×10-24cm3 ; (17)Surface Tension: 42.4 dyne/cm ; (18)Density: 1.109 g/cm3 ; (19)Flash Point: 77.4 °C ; (20)Enthalpy of Vaporization: 48.56 kJ/mol ; (21)Boiling Point: 204.4 °C at 760 mmHg ; (22)Vapour Pressure: 0.108 mmHg at 25°C
Uses of Actinomycin D: Actinomycin D is mainly used as an investigative tool in cell biology to inhibit transcription. Besides, Actinomycin D is one chemotherapy drug which has a long history, and has been used in therapy for many years. In additon, it is also used intravenously in treatment of a variety of cancers including gestational trophoblastic neoplasia, Wilms' tumor and rhabdomyosarcoma and so on.
When you are using Actinomycin D, please be cautious about it as the following: It is quite irritating to eyes, respiratory system and skin. When you are using this chemical, please wear suitable gloves and eye/face protection to avoid contact with skin and eyes. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Besides, it is very toxic by inhalation, in contact with skin and if swallowed. For instance, it may cause harm to the unborn child and may cause cancer, tough with limited evidence of a carcinogenic effect. Hence, in order not to breathe dust, you would better keep it locked up, and avoid exposure - obtain special instructions before use. After contact with skin, wash immediately with plenty of soap-suds.
You can still convert the following datas into molecular structure :
1.SMILES:O=C(O)C(N)(C)C
2.InChI:InChI=1/C4H9NO2/c1-4(2,5)3(6)7/h5H2,1-2H3,(H,6,7)
Toxic information of Actinomycin D can be showed as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
bird - wild | LD50 | oral | 1mg/kg (1mg/kg) | Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983. | |
cat | LDLo | intraperitoneal | 75ug/kg (0.075mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Antibiotiki. Vol. 16, Pg. 443, 1971. |
dog | LDLo | intravenous | 160ug/kg (0.16mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: LEUKOPENIA | National Technical Information Service. Vol. PB225-594, |
guinea pig | LD50 | unreported | 330ug/kg (0.33mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980. | |
hamster | LD50 | unreported | 600ug/kg (0.6mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980. | |
human | TDLo | intravenous | 40ug/kg/4D-I (0.04mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | New England Journal of Medicine. Vol. 281, Pg. 1094, 1969. |
mouse | LD50 | intraperitoneal | 750ug/kg (0.75mg/kg) | BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE IMMUNOLOGICAL INCLUDING ALLERGIC: DECREASED IMMUNE RESPONSE | Cancer Treatment Reports. Vol. 61, Pg. 103, 1977. |
mouse | LD50 | intravenous | 1025ug/kg (1.025mg/kg) | Antibiotiki. Vol. 16, Pg. 443, 1971. | |
mouse | LD50 | oral | 13mg/kg (13mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: OTHER CHANGES | Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960. |
mouse | LD50 | subcutaneous | 500ug/kg (0.5mg/kg) | "Antibiotics: Origin, Nature, and Properties," Korzyoski, T., et al., eds., Washington, DC, American Soc. for Microbiology, 1978Vol. 2, Pg. 1268, 1978. | |
mouse | LDLo | intratracheal | 1mg/kg (1mg/kg) | Toxicology Letters. Vol. 30, Pg. 63, 1986. | |
rabbit | LD50 | unreported | 150ug/kg (0.15mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980. | |
rat | LD50 | intraperitoneal | 100ug/kg (0.1mg/kg) | Acta Obstetrica et Gynaecologica Japonica, English Edition. Vol. 23, Pg. 219, 1976. | |
rat | LD50 | intravenous | 460ug/kg (0.46mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: OTHER CHANGES | Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960. |
rat | LD50 | oral | 7200ug/kg (7.2mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: OTHER CHANGES | Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960. |
rat | LD50 | subcutaneous | 800ug/kg (0.8mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: OTHER CHANGES | Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960. |